Do analysts recommend AIRS or MRAI?

AirSculpt Technologies currently has a consensus target price of $4.50, indicating a potential upside of 82.93%. Given AirSculpt Technologies' stronger consensus rating and higher probable upside, analysts plainly believe AirSculpt Technologies is more favorable than Marpai. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AirSculpt Technologies 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Marpai 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts recommend XGN or MRAI?

Exagen presently has a consensus price target of $9.63, indicating a potential upside of 28.16%. Given Exagen's stronger consensus rating and higher probable upside, equities analysts plainly believe Exagen is more favorable than Marpai. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Exagen 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.89 Marpai 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger earnings and valuation, XGN or MRAI?

Exagen has higher revenue and earnings than Marpai. Exagen is trading at a lower price-to-earnings ratio than Marpai, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Exagen $66.57M 2.73 -$19.95M -$0.81 N/A Marpai $34.87M 1.91 -$28.75M -$0.77 N/A

Is XGN or MRAI more profitable?

Exagen has a net margin of -26.61% compared to Marpai's net margin of -85.70%. Marpai's return on equity of 0.00% beat Exagen's return on equity. Company Net Margins Return on Equity Return on Assets Exagen -26.61% -104.46% -28.93% Marpai -85.70% N/A -100.23%

Do analysts prefer MRAI or LFMD?

LifeMD has a consensus target price of $7.57, indicating a potential upside of 146.63%. Given LifeMD's stronger consensus rating and higher possible upside, analysts clearly believe LifeMD is more favorable than Marpai. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Marpai 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 LifeMD 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.70

Which has higher valuation and earnings, MRAI or LFMD?

LifeMD has higher revenue and earnings than Marpai. LifeMD is trading at a lower price-to-earnings ratio than Marpai, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Marpai $34.87M 1.91 -$28.75M -$0.77 N/A LifeMD $194.05M 0.76 $14.35M -$0.05 N/A

Is MRAI or LFMD more profitable?

LifeMD has a net margin of 0.10% compared to Marpai's net margin of -85.70%. Marpai's return on equity of 0.00% beat LifeMD's return on equity. Company Net Margins Return on Equity Return on Assets Marpai -85.70% N/A -100.23% LifeMD 0.10% -168.23% -31.27%

Do analysts rate JYNT or MRAI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Joint 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Marpai 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher earnings & valuation, JYNT or MRAI?

Joint has higher revenue and earnings than Marpai. Marpai is trading at a lower price-to-earnings ratio than Joint, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Joint $54.90M 2.12 $2.91M $0.27 30.52 Marpai $34.87M 1.91 -$28.75M -$0.77 N/A

Is JYNT or MRAI more profitable?

Joint has a net margin of 6.49% compared to Marpai's net margin of -85.70%. Joint's return on equity of 12.02% beat Marpai's return on equity. Company Net Margins Return on Equity Return on Assets Joint 6.49% 12.02% 3.47% Marpai -85.70% N/A -100.23%

Which has higher earnings and valuation, CO or MRAI?

Global Cord Blood has higher revenue and earnings than Marpai. Marpai is trading at a lower price-to-earnings ratio than Global Cord Blood, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Global Cord Blood $1.24B 0.09 $79.04M $0.64 1.49 Marpai $34.87M 1.91 -$28.75M -$0.77 N/A

Is CO or MRAI more profitable?

Global Cord Blood has a net margin of 0.00% compared to Marpai's net margin of -85.70%. Company Net Margins Return on Equity Return on Assets Global Cord Blood N/A N/A N/A Marpai -85.70% N/A -100.23%

Marpai (MRAI) Competitors

$2.48 +0.14 (+5.77%)

As of 03:53 PM Eastern

Compare

MRAI vs. AIRS, XGN, LFMD, JYNT, and CO

Should you buy Marpai stock or one of its competitors? Marpai's main competitors and comparable companies include AirSculpt Technologies (AIRS), Exagen (XGN), LifeMD (LFMD), Joint (JYNT), and Global Cord Blood (CO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare providers & services" industry.

How does Marpai compare to AirSculpt Technologies?

AirSculpt Technologies (NASDAQ:AIRS) and Marpai (NASDAQ:MRAI) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation.

91.5% of AirSculpt Technologies shares are owned by institutional investors. Comparatively, 49.8% of Marpai shares are owned by institutional investors. 44.6% of AirSculpt Technologies shares are owned by company insiders. Comparatively, 46.1% of Marpai shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

AirSculpt Technologies currently has a consensus target price of $4.50, indicating a potential upside of 82.93%. Given AirSculpt Technologies' stronger consensus rating and higher probable upside, analysts plainly believe AirSculpt Technologies is more favorable than Marpai.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AirSculpt Technologies	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Marpai	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

AirSculpt Technologies has a net margin of -7.79% compared to Marpai's net margin of -85.70%. Marpai's return on equity of 0.00% beat AirSculpt Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AirSculpt Technologies	-7.79%	-5.83%	-2.88%
Marpai	-85.70%	N/A	-100.23%

AirSculpt Technologies has a beta of 2.26, indicating that its stock price is 126% more volatile than the broader market. Comparatively, Marpai has a beta of 4.74, indicating that its stock price is 374% more volatile than the broader market.

In the previous week, AirSculpt Technologies had 3 more articles in the media than Marpai. MarketBeat recorded 3 mentions for AirSculpt Technologies and 0 mentions for Marpai. AirSculpt Technologies' average media sentiment score of 0.59 beat Marpai's score of 0.00 indicating that AirSculpt Technologies is being referred to more favorably in the media.

Company	Overall Sentiment
AirSculpt Technologies	Positive
Marpai	Neutral

AirSculpt Technologies has higher revenue and earnings than Marpai. AirSculpt Technologies is trading at a lower price-to-earnings ratio than Marpai, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AirSculpt Technologies	$150.72M	1.18	-$11.67M	-$0.18	N/A
Marpai	$34.87M	1.91	-$28.75M	-$0.77	N/A

Summary

AirSculpt Technologies beats Marpai on 10 of the 15 factors compared between the two stocks.

How does Marpai compare to Exagen?

Exagen (NASDAQ:XGN) and Marpai (NASDAQ:MRAI) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, earnings, risk, profitability, institutional ownership, dividends and valuation.

Exagen has a net margin of -26.61% compared to Marpai's net margin of -85.70%. Marpai's return on equity of 0.00% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exagen	-26.61%	-104.46%	-28.93%
Marpai	-85.70%	N/A	-100.23%

In the previous week, Exagen had 3 more articles in the media than Marpai. MarketBeat recorded 3 mentions for Exagen and 0 mentions for Marpai. Exagen's average media sentiment score of 1.04 beat Marpai's score of 0.00 indicating that Exagen is being referred to more favorably in the media.

Company	Overall Sentiment
Exagen	Positive
Marpai	Neutral

75.3% of Exagen shares are owned by institutional investors. Comparatively, 49.8% of Marpai shares are owned by institutional investors. 10.4% of Exagen shares are owned by insiders. Comparatively, 46.1% of Marpai shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Exagen presently has a consensus price target of $9.63, indicating a potential upside of 28.16%. Given Exagen's stronger consensus rating and higher probable upside, equities analysts plainly believe Exagen is more favorable than Marpai.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exagen	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Marpai	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Exagen has a beta of 2.1, indicating that its stock price is 110% more volatile than the broader market. Comparatively, Marpai has a beta of 4.74, indicating that its stock price is 374% more volatile than the broader market.

Exagen has higher revenue and earnings than Marpai. Exagen is trading at a lower price-to-earnings ratio than Marpai, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exagen	$66.57M	2.73	-$19.95M	-$0.81	N/A
Marpai	$34.87M	1.91	-$28.75M	-$0.77	N/A

Summary

Exagen beats Marpai on 12 of the 17 factors compared between the two stocks.

How does Marpai compare to LifeMD?

Marpai (NASDAQ:MRAI) and LifeMD (NASDAQ:LFMD) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, profitability, dividends, media sentiment and institutional ownership.

LifeMD has a consensus target price of $7.57, indicating a potential upside of 146.63%. Given LifeMD's stronger consensus rating and higher possible upside, analysts clearly believe LifeMD is more favorable than Marpai.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Marpai	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
LifeMD	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

LifeMD has higher revenue and earnings than Marpai. LifeMD is trading at a lower price-to-earnings ratio than Marpai, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Marpai	$34.87M	1.91	-$28.75M	-$0.77	N/A
LifeMD	$194.05M	0.76	$14.35M	-$0.05	N/A

49.8% of Marpai shares are owned by institutional investors. Comparatively, 35.5% of LifeMD shares are owned by institutional investors. 46.1% of Marpai shares are owned by company insiders. Comparatively, 17.2% of LifeMD shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Marpai has a beta of 4.74, indicating that its share price is 374% more volatile than the broader market. Comparatively, LifeMD has a beta of 2.04, indicating that its share price is 104% more volatile than the broader market.

LifeMD has a net margin of 0.10% compared to Marpai's net margin of -85.70%. Marpai's return on equity of 0.00% beat LifeMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Marpai	-85.70%	N/A	-100.23%
LifeMD	0.10%	-168.23%	-31.27%

In the previous week, Marpai's average media sentiment score of 0.00 equaled LifeMD'saverage media sentiment score.

Company	Overall Sentiment
Marpai	Neutral
LifeMD	Neutral

Summary

LifeMD beats Marpai on 8 of the 14 factors compared between the two stocks.

How does Marpai compare to Joint?

Joint (NASDAQ:JYNT) and Marpai (NASDAQ:MRAI) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, media sentiment, risk and earnings.

Joint has a beta of 1.05, suggesting that its stock price is 5% more volatile than the broader market. Comparatively, Marpai has a beta of 4.74, suggesting that its stock price is 374% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Joint	0 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Marpai	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Joint has higher revenue and earnings than Marpai. Marpai is trading at a lower price-to-earnings ratio than Joint, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Joint	$54.90M	2.12	$2.91M	$0.27	30.52
Marpai	$34.87M	1.91	-$28.75M	-$0.77	N/A

Joint has a net margin of 6.49% compared to Marpai's net margin of -85.70%. Joint's return on equity of 12.02% beat Marpai's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Joint	6.49%	12.02%	3.47%
Marpai	-85.70%	N/A	-100.23%

In the previous week, Joint's average media sentiment score of 0.00 equaled Marpai'saverage media sentiment score.

Company	Overall Sentiment
Joint	Neutral
Marpai	Neutral

76.9% of Joint shares are held by institutional investors. Comparatively, 49.8% of Marpai shares are held by institutional investors. 30.2% of Joint shares are held by company insiders. Comparatively, 46.1% of Marpai shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Joint beats Marpai on 10 of the 12 factors compared between the two stocks.

How does Marpai compare to Global Cord Blood?

Global Cord Blood (NYSE:CO) and Marpai (NASDAQ:MRAI) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, valuation, earnings, dividends and media sentiment.

Global Cord Blood has a beta of 0.16, meaning that its share price is 84% less volatile than the broader market. Comparatively, Marpai has a beta of 4.74, meaning that its share price is 374% more volatile than the broader market.

49.8% of Marpai shares are owned by institutional investors. 0.5% of Global Cord Blood shares are owned by insiders. Comparatively, 46.1% of Marpai shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Global Cord Blood has higher revenue and earnings than Marpai. Marpai is trading at a lower price-to-earnings ratio than Global Cord Blood, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Global Cord Blood	$1.24B	0.09	$79.04M	$0.64	1.49
Marpai	$34.87M	1.91	-$28.75M	-$0.77	N/A

Global Cord Blood has a net margin of 0.00% compared to Marpai's net margin of -85.70%.

Company	Net Margins	Return on Equity	Return on Assets
Global Cord Blood	N/A	N/A	N/A
Marpai	-85.70%	N/A	-100.23%

In the previous week, Global Cord Blood's average media sentiment score of 0.00 equaled Marpai'saverage media sentiment score.

Company	Overall Sentiment
Global Cord Blood	Neutral
Marpai	Neutral

Summary

Global Cord Blood beats Marpai on 6 of the 10 factors compared between the two stocks.

Get Marpai News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MRAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MRAI vs. The Competition

Export

Metric	Marpai	Healthcare Providers & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$66.51M	$9.90B	$7.20B	$12.67B
Dividend Yield	N/A	2.57%	2.53%	8.56%
P/E Ratio	-0.94	34.75	272.63	25.27
Price / Sales	1.91	5.58	620.81	93.73
Price / Cash	N/A	121.27	76.98	52.08
Price / Book	-1.44	3.98	12.85	6.10
Net Income	-$28.75M	$310.54M	$3.47B	$348.86M
7 Day Performance	10.00%	-1.23%	-0.22%	-1.69%
1 Month Performance	10.99%	0.84%	8.04%	3.57%
1 Year Performance	79.35%	14.85%	25.08%	15.00%

Marpai Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MRAI Marpai	N/A	$2.48 +5.8%	N/A	+68.3%	$66.51M	$34.87M	N/A	150
AIRS AirSculpt Technologies	1.778 of 5 stars	$2.72 +1.9%	$4.50 +65.4%	-62.5%	$192.49M	$151.82M	N/A	240	Positive News
XGN Exagen	3.7576 of 5 stars	$7.67 +0.9%	$9.63 +25.5%	-27.8%	$184.11M	$66.57M	N/A	220	Positive News
LFMD LifeMD	2.9863 of 5 stars	$3.24 -0.3%	$7.57 +133.7%	-49.9%	$156.65M	$194.05M	N/A	230	Positive News
JYNT Joint	2.3981 of 5 stars	$8.54 +1.1%	N/A	-22.2%	$119.51M	$54.90M	31.63	320	Analyst Upgrade Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MRAI) was last updated on 9/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Marpai (MRAI) Competitors

MRAI vs. AIRS, XGN, LFMD, JYNT, and CO

How does Marpai compare to AirSculpt Technologies?

Summary

How does Marpai compare to Exagen?

Summary

How does Marpai compare to LifeMD?

Summary

How does Marpai compare to Joint?

Summary

How does Marpai compare to Global Cord Blood?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRAI vs. The Competition

Marpai Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Marpai (MRAI) Competitors

MRAI vs. AIRS, XGN, LFMD, JYNT, and CO

How does Marpai compare to AirSculpt Technologies?

Do insiders and institutionals believe in AIRS or MRAI?

Do analysts recommend AIRS or MRAI?

Is AIRS or MRAI more profitable?

Which has more volatility & risk, AIRS or MRAI?

Does the media favor AIRS or MRAI?

Which has preferable earnings & valuation, AIRS or MRAI?

Summary

How does Marpai compare to Exagen?

Is XGN or MRAI more profitable?

Does the media favor XGN or MRAI?

Do insiders & institutionals believe in XGN or MRAI?

Do analysts recommend XGN or MRAI?

Which has more volatility and risk, XGN or MRAI?

Which has stronger earnings and valuation, XGN or MRAI?

Summary

How does Marpai compare to LifeMD?

Do analysts prefer MRAI or LFMD?

Which has higher valuation and earnings, MRAI or LFMD?

Do institutionals and insiders believe in MRAI or LFMD?

Which has more risk & volatility, MRAI or LFMD?

Is MRAI or LFMD more profitable?

Does the media favor MRAI or LFMD?

Summary

How does Marpai compare to Joint?

Which has more risk & volatility, JYNT or MRAI?

Do analysts rate JYNT or MRAI?

Which has higher earnings & valuation, JYNT or MRAI?

Is JYNT or MRAI more profitable?

Does the media favor JYNT or MRAI?

Do insiders & institutionals have more ownership in JYNT or MRAI?

Summary

How does Marpai compare to Global Cord Blood?

Which has more risk & volatility, CO or MRAI?

Do insiders & institutionals believe in CO or MRAI?

Which has higher earnings and valuation, CO or MRAI?

Is CO or MRAI more profitable?

Does the media favor CO or MRAI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRAI vs. The Competition

Marpai Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools